CMO Merdad Parsey (Gilead)
October 28, 2020 05:37 PM EDT
R&D

Gilead hits the brakes on a tri­fec­ta of mid- and late-stage stud­ies for their trou­bled fil­go­tinib pro­gram. It's up to the FDA now

John Carroll

Editor & Founder

Nicole DeFeudis

Editor

Gilead $GILD ex­ecs haven’t de­cid­ed ex­act­ly what to do with fil­go­tinib in the wake of the slap­down at the FDA on their rheuma­toid arthri­tis …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Supreme Court to keep mulling state PBM dis­pute as US urges jus­tices to de­cline case

Large phar­ma com­pa­nies spell out rea­sons why tar­iffs will harm US in­vest­ments 

Mer­ck, Dai­ichi Sankyo scrap FDA ap­pli­ca­tion for HER3 ADC af­ter sur­vival miss

DNA gi­ant Il­lu­mi­na spawned an ecosys­tem of com­peti­tors and cus­tomers

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times